Effects of sodium tanshinone IIA sulfonate injection on inflammatory factors and vascular endothelial function in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials

Zunqi Kan, Wenli Yan, Mengqi Yang, Huanyu Gao, Dan Meng, Ning Wang, Yuqing Fang, Lingyu Wu, Yongmei SongFrontiers in Pharmacology 2023 · DOI

Introduction

Acute coronary syndrome (ACS) remains a significant global health challenge. While percutaneous coronary intervention (PCI) is the standard treatment for restoring blood flow, the procedure can inadvertently cause vascular endothelial damage, triggering inflammatory responses and oxidative stress. Sodium tanshinone IIA sulfonate (STS), a water-soluble derivative of the traditional Chinese herb Salvia miltiorrhiza (Danshen), has been used clinically to mitigate these effects. This systematic review and meta-analysis evaluates the efficacy and safety of STS as an adjunct therapy for ACS patients undergoing PCI.

Methods

Researchers conducted a systematic search across eight major databases and two clinical trial registries through October 2022. The study followed PRISMA guidelines to identify randomized controlled trials (RCTs) comparing STS plus conventional therapy against conventional therapy alone.

PRISMA flow chart of the literature screening and selection process.

A total of 17 RCTs involving 1,802 patients were included in the final analysis. Data were analyzed using RevMan 5.4 software, and study quality was assessed using the Cochrane Risk Assessment Tool 2.0.

Key Results

The meta-analysis revealed significant clinical and biochemical benefits associated with STS treatment:

  • Major Adverse Cardiovascular Events (MACE): STS treatment was associated with a 46% reduction in the risk of MACE (Relative Risk = 0.54, 95% CI [0.44, 0.66]).
  • Inflammatory Markers: Significant reductions were observed in high-sensitivity C-reactive protein (MD = -2.35 mg/L) and Tumor Necrosis Factor-alpha (SMD = -3.29).
  • Endothelial Function: Matrix metalloproteinase-9 (MMP-9) levels decreased significantly (MD = -16.24 ng/mL), while nitric oxide (NO) levels increased (MD = 3.23 μmol/L), indicating improved vessel health.
  • Oxidative Stress: STS treatment led to higher superoxide dismutase (SOD) levels (SMD = 1.46) and lower lipid peroxidation (LPO) levels (MD = -2.32 μmol/L), suggesting enhanced antioxidant defense.

Quality of Evidence and Limitations

While the quantitative results are promising, the overall quality of evidence was rated as very low to medium using the GRADE system. A primary concern is the risk of bias within the included studies.

Risk of bias summary for the included randomized controlled trials.

As shown in the risk assessment, many trials lacked detailed reporting on randomization, blinding, and allocation concealment. Furthermore, all 17 included studies were conducted in China, which may limit the generalizability of the findings to more diverse global populations.

Conclusion

Sodium tanshinone IIA sulfonate appears to be a safe and effective adjunct therapy for reducing systemic inflammation and improving clinical outcomes in ACS patients following PCI. However, due to the high risk of bias and geographic homogeneity of the current data, the authors call for large-scale, multi-center, double-blind RCTs to confirm these findings and establish STS as a standard global adjunct therapy.

Summary updated

Abstract

<b>Background:</b> Patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) therapy may experience further damage to the vascular endothelium, leading to increased inflammatory response and in-stent thrombosis. In many clinical studies, sodium tanshinone IIA sulfonate injection (STS) has been found to reduce inflammatory factors and enhance vascular endothelial function in patients with ACS while improving the prognosis of PCI. However, to date, there has been no systematic review assessing the effectiveness and safety of STS on inflammatory factors and vascular endothelial function. <b>Purpose:</b> The aim of this study is to systematically review the effects of STS on inflammatory factors and endothelial function in patients with ACS treated with PCI. <b>Methods:</b> Until October 2022, eight literature databases and two clinical trial registries were searched for randomized controlled trials (RCTs) investigating STS treatment for ACS patients undergoing PCI. The quality of the included studies was assessed using the Cochrane Risk Assessment Tool 2.0. Meta-analysis was performed using RevMan 5.4 software. <b>Results:</b> Seventeen trials met the eligibility criteria, including 1,802 ACS patients undergoing PCI. The meta-analysis showed that STS significantly reduced high-sensitivity C-reactive protein (hs-CRP) levels (mean difference [MD = -2.35, 95% CI (-3.84, -0.86), <i>p</i> = 0.002], tumor necrosis factor-alpha (TNF-α) levels (standard mean difference [SMD = -3.29, 95%CI (-5.15, -1.42), <i>p</i> = 0,006], matrix metalloproteinase-9 (MMP-9) levels [MD = -16.24, 95%CI (-17.24, -15.24), <i>p</i> < 0.00001], and lipid peroxidation (LPO) levels [MD = -2.32, 95%CI (-2.70, -1.93), <i>p</i> < 0.00001], and increased superoxide dismutase (SOD) levels [SMD = 1.46, 95%CI (0.43, 2.49), <i>p</i> = 0,006] in patients with ACS. In addition, STS significantly decreased the incidence of major adverse cardiovascular events (relative risk = 0.54, 95%CI [0.44, 0.66], <i>p</i> < 0.00001). The quality of evidence for the outcomes was assessed to be very low to medium. <b>Conclusion:</b> STS can safely and effectively reduce the levels of hs-CRP, TNF-α, MMP-9, and LPO and increase the level of SOD in patients with ACS treated with PCI. It can also reduce the incidence of adverse cardiovascular events. However, these findings require careful consideration due to the small number of included studies, high risk of bias, and low to moderate evidence. In the future, more large-scale and high-quality RCTs will be needed as evidence in clinical practice.
BibTeX
@inproceedings{kan2023effects,
  author = {Zunqi Kan and Wenli Yan and Mengqi Yang and Huanyu Gao and Dan Meng and Ning Wang and Yuqing Fang and Lingyu Wu and Yongmei Song},
  title = {{Effects of sodium tanshinone IIA sulfonate injection on inflammatory factors and vascular endothelial function in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials}},
  booktitle = {Frontiers in Pharmacology},
  year = {2023},
  doi = {10.3389/fphar.2023.1144419},
}
Figure